175 related articles for article (PubMed ID: 36799129)
1. Optimization of the Lead Compound NVP-BHG712 as a Colorectal Cancer Inhibitor.
Tröster A; DiPrima M; Jores N; Kudlinzki D; Sreeramulu S; Gande SL; Linhard V; Ludig D; Schug A; Saxena K; Reinecke M; Heinzlmeir S; Leisegang MS; Wollenhaupt J; Lennartz F; Weiss MS; Kuster B; Tosato G; Schwalbe H
Chemistry; 2023 Apr; 29(23):e202203967. PubMed ID: 36799129
[TBL] [Abstract][Full Text] [Related]
2. NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.
Tröster A; Heinzlmeir S; Berger BT; Gande SL; Saxena K; Sreeramulu S; Linhard V; Nasiri AH; Bolte M; Müller S; Kuster B; Médard G; Kudlinzki D; Schwalbe H
ChemMedChem; 2018 Aug; 13(16):1629-1633. PubMed ID: 29928781
[TBL] [Abstract][Full Text] [Related]
3. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.
Martiny-Baron G; Holzer P; Billy E; Schnell C; Brueggen J; Ferretti M; Schmiedeberg N; Wood JM; Furet P; Imbach P
Angiogenesis; 2010 Sep; 13(3):259-67. PubMed ID: 20803239
[TBL] [Abstract][Full Text] [Related]
4. Identification of Eph receptor signaling as a regulator of autophagy and a therapeutic target in colorectal carcinoma.
DiPrima M; Wang D; Tröster A; Maric D; Terrades-Garcia N; Ha T; Kwak H; Sanchez-Martin D; Kudlinzki D; Schwalbe H; Tosato G
Mol Oncol; 2019 Nov; 13(11):2441-2459. PubMed ID: 31545551
[TBL] [Abstract][Full Text] [Related]
5. Targeting EPHA2 with Kinase Inhibitors in Colorectal Cancer.
Tröster A; Jores N; Mineev KS; Sreeramulu S; DiPrima M; Tosato G; Schwalbe H
ChemMedChem; 2023 Dec; 18(23):e202300420. PubMed ID: 37736700
[TBL] [Abstract][Full Text] [Related]
6. Chemoproteomics-Aided Medicinal Chemistry for the Discovery of EPHA2 Inhibitors.
Heinzlmeir S; Lohse J; Treiber T; Kudlinzki D; Linhard V; Gande SL; Sreeramulu S; Saxena K; Liu X; Wilhelm M; Schwalbe H; Kuster B; Médard G
ChemMedChem; 2017 Jun; 12(12):999-1011. PubMed ID: 28544567
[TBL] [Abstract][Full Text] [Related]
7. The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study.
Kathawala RJ; Wei L; Anreddy N; Chen K; Patel A; Alqahtani S; Zhang YK; Wang YJ; Sodani K; Kaddoumi A; Ashby CR; Chen ZS
Oncotarget; 2015 Jan; 6(1):510-21. PubMed ID: 25402202
[TBL] [Abstract][Full Text] [Related]
8. The Pyrazolo[3,4-
Neuber C; Tröster A; Löser R; Belter B; Schwalbe H; Pietzsch J
Molecules; 2020 Nov; 25(21):. PubMed ID: 33153234
[TBL] [Abstract][Full Text] [Related]
9. Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation.
Giorgio C; Hassan Mohamed I; Flammini L; Barocelli E; Incerti M; Lodola A; Tognolini M
PLoS One; 2011 Mar; 6(3):e18128. PubMed ID: 21479221
[TBL] [Abstract][Full Text] [Related]
10. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
[TBL] [Abstract][Full Text] [Related]
11. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.
Chang Q; Jorgensen C; Pawson T; Hedley DW
Br J Cancer; 2008 Oct; 99(7):1074-82. PubMed ID: 18797457
[TBL] [Abstract][Full Text] [Related]
12. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.
Hassan-Mohamed I; Giorgio C; Incerti M; Russo S; Pala D; Pasquale EB; Zanotti I; Vicini P; Barocelli E; Rivara S; Mor M; Lodola A; Tognolini M
Br J Pharmacol; 2014 Dec; 171(23):5195-208. PubMed ID: 24597515
[TBL] [Abstract][Full Text] [Related]
13. The Functions of EphA1 Receptor Tyrosine Kinase in Several Tumors.
Wu Y; Du Z; Mou J; Qiu X; Chen J; Cai S; Ren D; Xiao F; Zhou G; Yuan C
Curr Med Chem; 2023; 30(20):2340-2353. PubMed ID: 35996244
[TBL] [Abstract][Full Text] [Related]
14. Exploring the potential of EphA2 receptor signaling pathway: a comprehensive review in cancer treatment.
Nehal M; Khatoon J; Akhtar S; Khan MKA
Mol Biol Rep; 2024 Feb; 51(1):337. PubMed ID: 38393520
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.
Hopfner M; Sutter AP; Huether A; Baradari V; Scherubl H
World J Gastroenterol; 2006 Sep; 12(35):5635-43. PubMed ID: 17007015
[TBL] [Abstract][Full Text] [Related]
16. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
17. Ligand recognition by A-class Eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex.
Himanen JP; Goldgur Y; Miao H; Myshkin E; Guo H; Buck M; Nguyen M; Rajashankar KR; Wang B; Nikolov DB
EMBO Rep; 2009 Jul; 10(7):722-8. PubMed ID: 19525919
[TBL] [Abstract][Full Text] [Related]
18. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
19. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.
Ferluga S; Hantgan R; Goldgur Y; Himanen JP; Nikolov DB; Debinski W
J Biol Chem; 2013 Jun; 288(25):18448-57. PubMed ID: 23661698
[TBL] [Abstract][Full Text] [Related]
20. Differential Kinobeads Profiling for Target Identification of Irreversible Kinase Inhibitors.
Dittus L; Werner T; Muelbaier M; Bantscheff M
ACS Chem Biol; 2017 Oct; 12(10):2515-2521. PubMed ID: 28876896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
